Development of a fluorescent reporter system to delineate cancer stem cells in triple-negative breast cancer

Stem Cells

Volumn 33, Issue 7, 2015, Pages 2114-2125

  Thiagarajan, Praveena S ^a   Hitomi, Masahiro ^a,b   Hale, James S ^a   Alvarado, Alvaro G ^a,b   Otvos, Balint ^a   Sinyuk, Maksim ^a   Stoltz, Kevin ^a   Wiechert, Andrew ^a   Mulkearns Hubert, Erin ^a   Jarrar, Awad M ^a   Zheng, Qiao ^a   Thomas, Dustin ^a,b   Egelhoff, Thomas T ^a,b,c   Rich, Jeremy N ^a,b,c   Liu, Huiping ^b,c   Lathia, Justin D ^a,b,c   Reizes, Ofer ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cancer stem cell; Fluorescent reporter system; Junctional adhesion molecule A; NANOG; Triple negative breast cancer

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; CD44V ANTIGEN; CELL SURFACE MARKER; GREEN FLUORESCENT PROTEIN; JUNCTIONAL ADHESION MOLECULE A; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; ENHANCED GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; DISEASE MARKER; EMBRYONIC STEM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REPORTER GENE; SCREENING; SELF CONCEPT; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; XENOGRAFT; ANIMAL; FEMALE; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; FEMALE; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84931571412     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2021     Document Type: Article

References (49)

1. American Cancer Society. Breast cancer facts and figures 2011-2012. Atlanta: American Cancer Society, Inc.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN,. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
3. Gluck S, Arteaga CL, Osborne CK,. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res 2011; 17: 5559-5561.
4. Dent R, Trudeau M, Pritchard KI, et al., Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
5. Rakha EA, El-Sayed ME, Green AR, et al., Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
6. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
7. Metzger-Filho O, Tutt A, de Azambuja E, et al., Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30: 1879-1887.
8. Andre F, Zielinski CC,. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 2012; 23 Suppl 6: vi46-51.
9. de Beca FF, Caetano P, Gerhard R, et al., Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013; 66: 187-191.
10. Idowu MO, Kmieciak M, Dumur C, et al., CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43: 364-373.
11. Uchoa Dde M, Graudenz MS, Callegari-Jacques SM, et al., Expression of cancer stem cell markers in basal and penta-negative breast carcinomas-a study of a series of triple-negative tumors. Pathol Res Pract 2014; 210: 432-439.
12. Meacham CE, Morrison SJ,. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-337.
13. Shackleton M, Quintana E, Fearon ER, et al., Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009; 138: 822-829.
14. Chuthapisith S, Eremin J, El-Sheemey M, et al., Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol 2010; 19: 27-32.
15. Phillips TM, McBride WH, Pajonk F,. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
16. Easwaran H, Tsai HC, Baylin SB,. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014; 54: 716-727.
17. Schmitt F, Ricardo S, Vieira AF, et al., Cancer stem cell markers in breast neoplasias: Their relevance and distribution in distinct molecular subtypes. Virchows Arch 2012; 460: 545-553.
18. Charafe-Jauffret E, Ginestier C, Iovino F, et al., Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
19. Charafe-Jauffret E, Ginestier C, Iovino F, et al., Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
21. Ohi Y, Umekita Y, Yoshioka T, et al., Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology 2011; 59: 776-780.
22. Tirino V, Desiderio V, Paino F, et al., Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J 2013; 27: 13-24.
23. Jeter CR, Badeaux M, Choy G, et al., Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27: 993-1005.
24. Kashyap V, Rezende NC, Scotland KB, et al., Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 2009; 18: 1093-1108.
25. Nagata T, Shimada Y, Sekine S, et al., Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 2014; 21: 96-101.
26. Ali HR, Dawson SJ, Blows FM, et al., Cancer stem cell markers in breast cancer: Pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13: R118.
27. Cariati M, Naderi A, Brown JP, et al., Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008; 122: 298-304.
28. Zhou L, Jiang Y, Yan T, et al., The prognostic role of cancer stem cells in breast cancer: A meta-analysis of published literatures. Breast Cancer Res Treat 2010; 122: 795-801.
29. Zheng Q, Banaszak L, Fracci S, et al., Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer 2013; 20: 797-808.
30. Lathia JD, Li M, Sinyuk M, et al., High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Rep 2014; 6: 117-129.
31. Sukhdeo K, Paramban RI, Vidal JG, et al., Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. PLoS One 2013; 8: e53015.
32. Liu H, Patel MR, Prescher JA, et al., Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120.
33. Goswami S, Sahai E, Wyckoff JB, et al., Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005; 65: 5278-5283.
34. Lathia JD, Gallagher J, Heddleston JM, et al., Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-432.
35. Meyer MJ, Fleming JM, Lin AF, et al., CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010; 70: 4624-4633.
36. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
37. Gotte M, Mohr C, Koo CY, et al., miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 6569-6580.
38. McSherry EA, McGee SF, Jirstrom K, et al., JAM-A expression positively correlates with poor prognosis in breast cancer patients. Int J Cancer 2009; 125: 1343-1351.
39. Murakami M, Giampietro C, Giannotta M, et al., Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression. PLoS One 2011; 6: e21242.
40. Li X, Lewis MT, Huang J, et al., Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
41. Stewart JM, Shaw PA, Gedye C, et al., Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011; 108: 6468-6473.
42. Yu L, Liu S, Zhang C, et al., Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget 2013; 4: 2326-2338.
43. Tang B, Raviv A, Esposito D, et al., A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Reports 2015; 4: 155-169.
44. Badeaux MA, Jeter CR, Gong S, et al., In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals. Cell Cycle 2013; 12: 2395-2408.
45. Jeter CR, Liu B, Liu X, et al., NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 30: 3833-3845.
46. Naik TU, Naik MU, Naik UP,. Junctional adhesion molecules in angiogenesis. Front Biosci 2008; 13: 258-262.
47. Naik UP, Naik MU,. Putting the brakes on cancer cell migration: JAM-A restrains integrin activation. Cell Adh Migr 2008; 2: 249-251.
48. McSherry EA, Brennan K, Hudson L, et al., Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res 2011; 13: R31.
49. Goetsch L, Haeuw JF, Beau-Larvor C, et al., A novel role for junctional adhesion molecule-A in tumor proliferation: Modulation by an anti-JAM-A monoclonal antibody. Int J Cancer 2013; 132: 1463-1474.